U.S. Markets closed

Brief Commentary On Summit Therapeutics plc's (LON:SUMM) Fundamentals

Simply Wall St

Summit Therapeutics plc (LON:SUMM) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case of SUMM, it is a financially-healthy company with a great history of performance, trading at a great value. In the following section, I expand a bit more on these key aspects. For those interested in digging a bit deeper into my commentary, read the full report on Summit Therapeutics here.

Undervalued with excellent balance sheet

SUMM has a strong track record of performance. In the previous year, SUMM delivered an impressive double-digit return of 24%. Not surprisingly, SUMM outperformed its industry which returned 22%, giving us more conviction of the company's capacity to drive bottom-line growth going forward. SUMM is financially robust, with ample cash on hand and short-term investments to meet upcoming liabilities. This suggests prudent control over cash and cost by management, which is an important determinant of the company’s health. Looking at SUMM's capital structure, the company has no debt on its balance sheet. This implies that the company is running its operations purely on off equity funding. which is typically normal for a small-cap company. SUMM has plenty of financial flexibility, without debt obligations to meet in the short term, as well as the headroom to raise debt should it need to in the future.

AIM:SUMM Income Statement, August 7th 2019

SUMM's shares are now trading at a price below its true value based on its discounted cash flows, indicating a relatively pessimistic market sentiment. Investors have the opportunity to buy into the stock to reap capital gains, if SUMM's projected earnings trajectory does follow analyst consensus growth, which determines my intrinsic value of the company. Also, relative to the rest of its peers with similar levels of earnings, SUMM's share price is trading below the group's average. This further reaffirms that SUMM is potentially undervalued.

AIM:SUMM Price Estimation Relative to Market, August 7th 2019

Next Steps:

For Summit Therapeutics, there are three key factors you should further examine:

  1. Future Outlook: What are well-informed industry analysts predicting for SUMM’s future growth? Take a look at our free research report of analyst consensus for SUMM’s outlook.
  2. Dividend Income vs Capital Gains: Does SUMM return gains to shareholders through reinvesting in itself and growing earnings, or redistribute a decent portion of earnings as dividends? Our historical dividend yield visualization quickly tells you what your can expect from SUMM as an investment.
  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of SUMM? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.